What Matters: realizing value for innovation

Overcoming hurdles to market access is no small matter. Increasingly, cost-effectiveness and cost-containment are trumping safety and efficacy. What Matters is the place to examine and address the challenges facing biopharma in gaining market access.

If your passion is realizing value for innovation, welcome to the conversation.


The Real-World Consequences of Classification

Simply enter the question "are eggs dairy?" in your favorite search engine to experience how classification can shape our view of the world. The search results will include all kinds of articles, discussions, and even videos from people asking and trying to answer this question—generally because eggs are placed in the dairy section of most US grocery stores.

This implicit classification leads many people in the US to believe that eggs are dairy. This may be a surprising assumption to those in other countries such as the UK where eggs are kept in the dry goods section. We often are not aware of the way classification shapes our perceptions and decisions. Classification of eggs in the grocery store is, for most of us, a low-stakes problem. Classification of pharmaceutical products, on the other hand, can have massive clinical and economic effects, but for most individuals, the classification is just as invisible.

Part IV: 4 Market Access Assumptions Misleading Biotechs

In this series, we have been examining the common market access misconceptions that can create challenges for biotech companies during the drug development lifecycle. In the final installment, we will explore the fourth assumption—if clinical results are great, then the cost of a drug is of no concern.

With budgets getting tighter and populations growing older, governments are striving to keep a tight rein on medical costs while simultaneously ensuring that innovative treatments are accessible to the people. In order to run a sustainable healthcare system, many countries have been increasingly focused on getting the best value for their money. As such, biopharma companies have been forced to justify the price of the drug relative to its benefits. 

Part III: 4 Market Access Assumptions Misleading Biotechs

Part III: Global market access planning begins after phase III clinical trials

A founding principle for Context Matters is the connection between clinical trial design with regulatory and reimbursement decisions—the earlier you start thinking about market access the better. Aubagio® offers a great example of the connection of clinical trial design with reimbursement and regulatory decisions.

Part II: 4 Market Access Assumptions Misleading Biotechs

The health technology assessment (HTA) process takes time, but how much delay in market access should you expect? The time it takes for an HTA agency to issue a reimbursement decision can be a major factor in the overall market access timeline. While HTA agencies publish timelines to set an expectation, those timelines are not always adhered to and decisions that take longer slow down speed to market. This can result in significant business repercussions for the manufacturer including decreased ability to gain market share and increase in time to revenue generation. So, when formulating a market access strategy, an understanding of the observed time for decision versus the published timelines can help to plan and set appropriate expectations. We also want to identify other important factors of market access that take place after a decision is issued and have the potential to affect market access.

4 Market Access Assumptions Misleading Biotechs

Biotechnology companies often do not have the market access resources comparable to large pharma. While this can pose a challenge, there is a considerable opportunity for biotechs to reduce this disadvantage by using health technology assessment (HTA) data in innovative ways to inform and drive their market access decision-making.

With our innovative technology platform and focus on data quality, we have been helping biotech companies understand the market access space for bellwether HTA agencies for the past seven years. Throughout our experience with biotechnology companies, we continually see four assumptions about the HTA process and market access:

Accelerating Immuno-Oncology Therapies to Market

In their 2015 industry report, the Pharmaceutical Research and Manufacturers of America (PhRMA) estimated over 800 cancer therapies were in the industry pipeline—citing that approximately 80% of these drugs have the potential to be first-in-class medicines. One of the most groundbreaking areas in oncology today is checkpoint inhibitor immuno-oncology (I-O) treatments, with the American Society of Clinical Oncology (ASCO) naming immunotherapy as its 2016 Advance of the Year. Checkpoint inhibitor I-O treatments unlock immune system cells, allowing the cells to recognize and fight cancer tumors, and have shown early efficacy gains that have given hope to many oncology researchers, physicians, and patients. An exciting breakthrough that raises the question—what is the fastest and safest way to get these new treatments to patients?